Impact of new Joint British Societies’ (JBS 2) guidelines on prevention of cardiovascular disease: evaluation of serum total cholesterol goal achievement in UK clinical practice

References

• Department of Health. Coronary heart disease: national service framework for coronary heart disease. Modern standards and service models (2000). Available at http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4094275. Accessed July 19, 2005
   Google Scholar
• Department of Health. Health survey for England 2003. Available at http://www.dh.gov.uk/PublicationsAndStatistics/Publications/PublicationsStatistics/PublicationsStatisticsArticle/fs/en?CONTENT_ID=4098712&chk=F4kphd Accessed November 3, 2006
   Google Scholar
• Wood DA, Durrington P, Poulter N, et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998;80:S1–29
   PubMed Web of Science ®Google Scholar
• Joint British Societies. JBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91(Suppl 5):v1–52
   PubMedGoogle Scholar
• Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000;101:207–13
   PubMed Web of Science ®Google Scholar
• Roberts WC. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs. Am J Cardiol 1997;80:106–7
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307–16
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Færgeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294:2437–45
   PubMed Web of Science ®Google Scholar
• Cayley WE Jr. High-dose statins and the IDEAL study [letter]. JAMA 2006;295:2476
   PubMedGoogle Scholar
• Ong HT, Cheah JS. High-dose statins and the IDEAL study [letter]. JAMA 2006;295:2476–7
   PubMedGoogle Scholar
• Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40:2125–34
   PubMed Web of Science ®Google Scholar
• Gagné C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084–91
   Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107:2409–15
   PubMed Web of Science ®Google Scholar
• Stein E, Stender S, Mata P, et al. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin. Am Heart J 2004;148:447–55
   PubMed Web of Science ®Google Scholar
• Kosoglou T, Statkevich P, Yang B, et al. Pharmacodynamic interaction between ezetimibe and rosuvastatin. Curr Med Res Opin 2004;20:1185–95
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005;80:587–95
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, et al. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am J Cardiol 2004;93:1487–94
   PubMed Web of Science ®Google Scholar
• Cruz-Fernandez JM, Bedarida GV, Adgey J, et al. Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease. Int J Clin Pract 2005;59:619–27
   Google Scholar
• Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005;149:464–73
   PubMed Web of Science ®Google Scholar
• Brohet C, Banai S, Alings AM, et al. LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia. Curr Med Res Opin 2005;21:571–8
   PubMed Web of Science ®Google Scholar
• Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev Cardiovasc Ther 2006;4:461–6
   PubMedGoogle Scholar
• Armstrong EP, Zachry WM, III, Malone DC. Cost-effectiveness analysis of simvastatin and lovastatin/extended-release niacin to achieve LDL and HDL goal using NHANES data. J Manag Care Pharm 2004;10:251–8
   PubMedGoogle Scholar
• Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002;89:672–8
   PubMed Web of Science ®Google Scholar
• Stein EA, Davidson MH, Dujovne CA, et al. Efficacy and tolerability of low-dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial. J Cardiovasc Pharmacol Ther 1996;1:107–16
   PubMedGoogle Scholar
• Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004;147:705–13
   PubMed Web of Science ®Google Scholar
• Stender S, Schuster H, Barter P, et al. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes Metab 2005;7:430–8
   PubMed Web of Science ®Google Scholar
• Bots AF, Kastelein JJ. Achieving lipid goals in real life: the Dutch DISCOVERY study. Int J Clin Pract 2005;59:1387–94
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Southworth H. Achievement of English National Service Framework lipid-lowering goals: pooled data from recent comparative treatment trials of statins at starting doses. Int J Clin Pract 2005;59:1171–7
   PubMed Web of Science ®Google Scholar
• Van Ganse E, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005;21:1389–99
   PubMed Web of Science ®Google Scholar
• Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996;164:208–11
   Google Scholar
• Thiebaud P, Patel BV, Nichol MB, et al. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care 2005;11:670–4
   PubMed Web of Science ®Google Scholar
• McKenney JM, Davidson MH, Saponaro J, et al. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol 2005;46:594–9
   PubMed Web of Science ®Google Scholar
• Martineau P, Gaw A, de Teresa E, et al. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. Atherosclerosis 2006. e-published ahead of print
   Google Scholar
• Fornengo P, Bruno G, De Salvia A, et al. Low adherence of general practitioners to National Cholesterol Education Program guidelines for the management of hyperlipidaemia. Diabetes Nutr Metab 2000;13:263–8
   PubMedGoogle Scholar
• Andrade SE, Walker AM, Gottlieb LK, et al. Discontinuation of antihyperlipidemic drugs – do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125–31
   PubMed Web of Science ®Google Scholar
• Troein M, Rastam L, Selander S. Changes in health beliefs after labelling with hypercholesterolaemia. Scand J Public Health 2002;30:76–9
   Google Scholar
• Simpson RJ, Jr. Challenges for improving medication adherence. JAMA 2006;296:2614–16
   PubMed Web of Science ®Google Scholar
• Cheng S, Lichtman JH, Amatruda JM, et al. Knowledge of cholesterol levels and targets in patients with coronary artery disease. Prev Cardiol 2005;8:11–17
   PubMedGoogle Scholar
• Nash IS, Mosca L, Blumenthal RS, et al. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med 2003;163:1597–1600
   PubMed Web of Science ®Google Scholar
• Sacks FM. Adherence to statin therapy: why aren’t we doing better? Am J Med 2002;113:685–6
   PubMed Web of Science ®Google Scholar
• Durack-Brown I, Giral P, d’Ivernois J-F, et al. Patients’ and physicians’ perceptions and experience of hypercholesterolemia: a qualitative study. Br J Gen Pract 2003;53:851–7
   Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487–97
   PubMed Web of Science ®Google Scholar
• Frolkis JP, Zyzanski SJ, Schwartz JM, et al. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98:851–5
   PubMed Web of Science ®Google Scholar
• McBride P, Schrott HG, Plane MB, et al. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238–44
   PubMed Web of Science ®Google Scholar
• Cabana MD, Rand CS, Powe NR, et al. Why don’t physicians follow clinical practice guidelines? A framework for improvement. JAMA 1999;282:1458–65
   PubMed Web of Science ®Google Scholar
• Kedward J, Dakin L. A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care. Br J Gen Pract 2003;53:684–9
   PubMed Web of Science ®Google Scholar
• Hobbs FD, Erhardt L. Acceptance of guideline recommendations and perceived implementation of coronary heart disease prevention among primary care physicians in five European countries: the Reassessing European Attitudes about Cardiovascular Treatment (REACT) survey. Fam Pract 2002;19:596–604
   PubMed Web of Science ®Google Scholar
• Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563–71
   Google Scholar
• National Institute for Health and Clinical Excellence. Clinical guidelines under development: lipid modification. Cardiovascular risk assessment: the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. Available at http://www.nice.org.uk/page.aspx?o=guidelines.inprogress.hyperlipidaemiacardiovascular Accessed November 23, 2006
   Google Scholar
• Backlund L, Skaner Y, Montgomery H, et al. GPs’ decisions on drug treatment for patients with high cholesterol values: a think-aloud study. BMC Med Inform Decis Mak 2004;4:23–34
   PubMedGoogle Scholar
• Adult Treatment Panel. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001;285:2486–97
   PubMed Web of Science ®Google Scholar
• Benner JS, Tierce JC, Ballantyne CM, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics 2004;22 Suppl 3:13–23
   PubMed Web of Science ®Google Scholar